Usha Sharma – Mumbai
The Rs 15 crore Mumbai-based pharmaceutical company, Amra Remedies, established in 2010 has targeted a turnover of Rs 100 crore in financial year 2012-13. The company also plans to enter the diabetes therapeutic segment by 2014 and provide full line of treatment. It is currently in talks with a Japanese company manufacturing glucometers and a multinational company for obtaining co-marketing rights for the Indian market.
Talking exclusively with Express Pharma, Partha Banerjee, MD and CEO, Amra Remedies said, “We are in talks with the Japanese company for co-marketing of their glucometers in India. With the help of this agreement, we will be able provide to full line of treatment to patients. We are also in talks with another multinational pharma company as they hold the patent on our research molecule. We are in the final stages of discussion for co-marketing the diabetes product in India. Presently, it is available globally and we are targeting to launch the product by 2014 in India.”
Presently, Amra Remedies has over 45 products in its kitty for cardiovascular, dermatology, gynaecology, oncology, nutraceutical, anti-microbial, gastrointestinal and respiratory therapeutic segments. To continue its growth, the company plans to launch has five more new products in its existing therapeutic areas (two for dermatology and one each for anti-microbial, oncology and FMCG).
Banerjee highlighted, “We are mainly focusing on the anti-microbial therapeutic segment as we consider that this therapeutic segment has major scope and there is unmet demand in the market.”
With a manpower strength of 850, Amara Remedies plans to hire 650 more by 2013. 90 per cent of the new recruitment will be medical representatives as it has extensive expansion plans in order to have a pan India presence.
While sharing the company’s future plans, he mentioned, “As of now, we don’t have any plans to establish our presence in the international market. We feel that the domestic market has better promise and good business opportunities for companies like us. Presently we do not own any manufacturing facility but we are in the process of acquiring one manufacturing facility in Mumbai, which will be in an excise free zone. Both the facilities are likely to get commissioned by 2014. Overall, we have a capex plan of Rs 40-45 crore.”
The company has recently introduced toilet seat sanitizer spray elav O in India.